|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> Starting from the BXPC3 cell line, we generated and profiled a TRAIL-resistant model of pancreatic cancer, testing the impact of the combined treatment <i>in vitro</i> with specific cytotoxicity and metabolic assays.
|
30809285 |
2019 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, the results indicate that CQ in combination with TRAIL may be useful to treat human pancreatic cancer.
|
29513749 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast-enriched tumor microenvironment.
|
30075209 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TRAIL/NF-κB/CX3CL1 Mediated Onco-Immuno Crosstalk Leading to TRAIL Resistance of Pancreatic Cancer Cell Lines.
|
29867042 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We observed that TRAIL-resistant pancreatic cancer cells had higher levels of HOTAIR expression, whereas TRAIL-sensitive pancreatic cancer cells had lower HOTAIR levels.
|
28476883 |
2017 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression.
|
28476028 |
2017 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer.
|
28188806 |
2017 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LPS promotes resistance to TRAIL-induced apoptosis in pancreatic cancer.
|
28572836 |
2017 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The TRAIL mice displayed significantly decreased tumor volumes and an enhanced overall survival in pancreatic cancer.
|
26390425 |
2016 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that the novel CTL harboring Lenti/hCD40L/E1AB and Ad5/35-TRAIL inhibited pancreatic cancer cell growth and angiogenesis in vitro and in vivo.
|
27876704 |
2016 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we demonstrated that survivin downregulation with TRAIL expression greatly enhanced the cytotoxic death of pancreatic cancer cells after gemcitabine treatment.
|
26677013 |
2016 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our studies support the use of these readily available CaM antagonists combined with TRAIL-activating agents for pancreatic cancer therapy.
|
26320171 |
2015 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inhibitor, PH11.
|
25684663 |
2015 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TRAIL treatment increased ROS in two TRAIL-sensitive pancreatic cancer cell lines, MiaPaCa-2 and BxPC-3, but ROS were involved in TRAIL-induced apoptosis only in MiaPaCa-2 cells.
|
26000607 |
2015 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill.
|
26138346 |
2015 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
|
25482930 |
2014 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.
|
23833311 |
2013 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeted inhibition of OPG binding to TRAIL may represent a therapeutic approach in the treatment of pancreatic cancer.
|
23219833 |
2013 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results indicate that MUC5AC inhibits TRAIL‑induced apoptosis in human pancreatic cancer and may serve as an important indicator in diagnosis and prognosis.
|
23292004 |
2013 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer.
|
24204567 |
2013 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report that DHA enhances the efficacy of Apo2L/TRAIL for the treatment of pancreatic cancer.
|
22666346 |
2012 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined treatment with oncolytic adenovirus-mediated hSSTr2 and TRAIL gene provides the rationale for a clinical trial in pancreatic cancer.
|
19671855 |
2009 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study explored the possibility of sensitizing pancreatic cancer to gemcitabine chemotherapy by combining the chemotherapy with the proapoptotic genes Bax and TNF-related apoptosis-inducing ligand (TRAIL).
|
17984977 |
2008 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TRAIL can stimulate the expression of uPA, IL-8, MMP-7 and MMP-9 in pancreatic cancer cell lines, especially in Colo357wt.
|
18397859 |
2008 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, our findings for the first time indicate that targeting XIAP represents a promising strategy to enhance the antitumor activity of TRAIL in pancreatic cancer, which has important clinical implications.
|
16832350 |
2007 |